OVERVIEW

Tay-Sachs and Sandhoff Diseases: Unlocking the Mystery for Treatment and Management of Late-Onset Patients is organized by EXCEL Continuing Education.

Released On: August 24, 2022
Expires On: September 24, 2023

Program Overview:
GM2 gangliosidoses conditions, including Tay-Sachs disease, Sandhoff disease, and GM2 activator, represent a disease continuum dependent on the amount of residual lysosomal hexosaminidase a enzyme activity. This CME on-demand webinar will offer access to the latest information and best practices to facilitate the early recognition of signs and symptoms and accurate diagnosis of late-onset juvenile and late-onset adult forms of Tay-Sachs and Sandhoff diseases. Furthermore, faculty will discuss sample case presentations and explore evolving evidence on emerging therapies and their potential role within current management approaches, as well as strategies for improved care coordination and opportunities to support patients and their families.

Learning Objectives:
Upon completion of this activity, participants should be better able to:
• Review the pathogenesis of GM2 gangliosidoses
• Recognize clinical features, signs, and symptoms in patients with Tay-Sachs and Sandhoff diseases
• Demonstrate how to utilize genetic testing as part of a diagnostic approach to differentiate Tay-Sachs and Sandhoff diseases from other disorders
• Identify and address needs of individual patients to provide supportive care services and optimal patient outcome
• Evaluate emerging GM2 Gangliosidosis disease-modifying therapies and practice implications